Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design

Abstract Background Chronic active antibody-mediated rejection (AMR) is a major cause of graft loss with no approved drugs for its treatment. Currently, off-label regimens are used, reflecting the high unmet need for effective therapies based on well-controlled trials. Clazakizumab is a high-affinit...

Full description

Bibliographic Details

Published in:	Trials
Main Authors:	Peter W. Nickerson, Georg A. Böhmig, Steve Chadban, Deepali Kumar, Roslyn B. Mannon, Teun van Gelder, James C. Lee, Scott Adler, Edward Chong, Arjang Djamali
Format:	Article
Language:	English
Published:	BMC 2022-12-01
Subjects:	Chronic active antibody-mediated rejection Clazakizumab Estimated glomerular filtration rate Kidney transplantation
Online Access:	https://doi.org/10.1186/s13063-022-06897-3